BRPI0822651A2 - Subfamília b de adenovírus sadv-28, -27, 29, -32, -33 e -35 de símio e seus usos - Google Patents

Subfamília b de adenovírus sadv-28, -27, 29, -32, -33 e -35 de símio e seus usos

Info

Publication number
BRPI0822651A2
BRPI0822651A2 BRPI0822651-2A2A BRPI0822651A BRPI0822651A2 BR PI0822651 A2 BRPI0822651 A2 BR PI0822651A2 BR PI0822651 A BRPI0822651 A BR PI0822651A BR PI0822651 A2 BRPI0822651 A2 BR PI0822651A2
Authority
BR
Brazil
Prior art keywords
sadv
subfamily
adenovirus
adenovirus subfamily
Prior art date
Application number
BRPI0822651-2A2A
Other languages
English (en)
Inventor
Soumitra Roy
James M Wilson
Luc H Vandenberghe
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of BRPI0822651A2 publication Critical patent/BRPI0822651A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0822651-2A2A 2007-11-28 2008-11-24 Subfamília b de adenovírus sadv-28, -27, 29, -32, -33 e -35 de símio e seus usos BRPI0822651A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US454207P 2007-11-28 2007-11-28
US446607P 2007-11-28 2007-11-28
US456707P 2007-11-28 2007-11-28
US453307P 2007-11-28 2007-11-28
US453407P 2007-11-28 2007-11-28
US453107P 2007-11-28 2007-11-28
PCT/US2008/013065 WO2009073103A2 (en) 2007-11-28 2008-11-24 Simian subfamily b adenoviruses sadv-28,27,-29,-32,-33, and -35 and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0822651A2 true BRPI0822651A2 (pt) 2014-10-14

Family

ID=40718407

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822651-2A2A BRPI0822651A2 (pt) 2007-11-28 2008-11-24 Subfamília b de adenovírus sadv-28, -27, 29, -32, -33 e -35 de símio e seus usos

Country Status (20)

Country Link
US (3) US8524219B2 (pt)
EP (1) EP2220242B1 (pt)
JP (3) JP5740157B2 (pt)
KR (3) KR101614362B1 (pt)
CN (1) CN101883857B (pt)
AU (2) AU2008331905B2 (pt)
BR (1) BRPI0822651A2 (pt)
CA (1) CA2706257C (pt)
CY (1) CY1118866T1 (pt)
DK (1) DK2220242T3 (pt)
ES (1) ES2621165T3 (pt)
HR (1) HRP20170395T1 (pt)
HU (1) HUE031636T2 (pt)
LT (1) LT2220242T (pt)
MX (3) MX344106B (pt)
PL (1) PL2220242T3 (pt)
PT (1) PT2220242T (pt)
SG (2) SG186022A1 (pt)
SI (1) SI2220242T1 (pt)
WO (1) WO2009073103A2 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101883858B (zh) 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
WO2010051367A1 (en) 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
CA2762203A1 (en) 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
SG11201407343XA (en) 2012-05-18 2014-12-30 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
EP4523756A3 (en) 2015-02-13 2025-05-28 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
BR112017026523A2 (pt) * 2015-06-12 2018-08-14 Glaxosmithkline Biologicals Sa vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
EP3384035A4 (en) 2015-12-02 2019-08-07 Voyager Therapeutics, Inc. ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
KR102427379B1 (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
IL315358A (en) 2016-08-18 2024-11-01 Univ California CRISPR-CAS genome engineering using a modular AAV delivery system
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
KR20210019996A (ko) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 조성물 및 방법
WO2019241486A1 (en) 2018-06-13 2019-12-19 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
EP3823981A4 (en) 2018-07-17 2022-04-06 Neuromyon Inc. TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTS EXPRESSING IGF-1 ISOFORMS
CN112770812A (zh) 2018-07-24 2021-05-07 沃雅戈治疗公司 产生基因治疗制剂的系统和方法
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
WO2020072844A1 (en) 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
CN113166781A (zh) 2018-10-15 2021-07-23 沃雅戈治疗公司 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
WO2020160508A1 (en) 2019-01-31 2020-08-06 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids
NL2023464B1 (en) * 2019-07-09 2021-02-02 Academisch Ziekenhuis Leiden Oncolytic Non-human adenoviruses and uses thereof
CN116322740A (zh) 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2022218997A1 (en) 2021-04-12 2022-10-20 Centre National De La Recherche Scientifique (Cnrs) Novel universal vaccine presenting system
US20250197885A1 (en) * 2022-03-10 2025-06-19 Technovax, Inc. Recombinant virus-like particle capsid vaccines against adenoviruses and compositions, methods, and use thereof
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
CN117089577B (zh) * 2023-08-21 2024-06-25 暨南大学 重组的猴腺病毒、病毒载体及构建方法
CN117143833B (zh) * 2023-08-21 2024-06-04 暨南大学 一种猴腺病毒毒株及其应用
US20250276095A1 (en) 2024-03-04 2025-09-04 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
WO2025226842A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Expression control by drg-expressed mirnas
WO2025226841A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Gene therapy approach for treating disorders associated with tnnt2
WO2026011008A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Expression control by skeletal muscle-expressed mirnas
WO2026011009A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Compositions and methods for muscle disorders
WO2026030242A1 (en) 2024-07-29 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
WO2026030244A1 (en) 2024-07-30 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
WO2026050402A1 (en) 2024-08-29 2026-03-05 Kate Therapeutics, Inc. Liver de-targeted muscle tropic capsids

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
AU1822499A (en) 1997-12-12 1999-06-28 Saint Louis University Ctip, a novel protein that interacts with ctbp and uses therefor
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
KR20040043129A (ko) * 2001-06-22 2004-05-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물
EP1409748B1 (en) 2001-06-22 2011-10-26 The Trustees of The University of Pennsylvania Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof.
AU2002365366B2 (en) * 2001-11-21 2007-05-10 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US7291498B2 (en) * 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
CA2528511C (en) * 2003-06-20 2015-11-03 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
DE602005017743D1 (de) 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
WO2006003521A1 (en) * 2004-02-06 2006-01-12 Monash University High dose, short interval use of sulfated polysaccharides for the treatment of infections
EA016648B1 (ru) * 2004-10-14 2012-06-29 Круселл Холланд Б.В. Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии
AR053275A1 (es) * 2005-05-12 2007-04-25 Glaxo Group Ltd Composicion de vacuna
EP2012822B1 (en) 2006-04-28 2010-01-20 The Trustees of the University of Pennsylvania Modified adenovirus hexon protein and uses thereof
CN102131920B (zh) 2007-11-28 2013-11-06 宾夕法尼亚大学托管会 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用
CN101883858B (zh) 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用

Also Published As

Publication number Publication date
US8524219B2 (en) 2013-09-03
WO2009073103A3 (en) 2010-05-20
SG186022A1 (en) 2012-12-28
PL2220242T3 (pl) 2017-09-29
CY1118866T1 (el) 2018-01-10
AU2008331905A1 (en) 2009-06-11
EP2220242B1 (en) 2016-12-28
KR20160119251A (ko) 2016-10-12
AU2008331905B2 (en) 2014-09-18
CN101883857B (zh) 2015-08-12
KR101614362B1 (ko) 2016-04-22
AU2014277699B2 (en) 2017-04-06
WO2009073103A2 (en) 2009-06-11
CA2706257A1 (en) 2009-06-11
US9206238B2 (en) 2015-12-08
JP2016214242A (ja) 2016-12-22
SI2220242T1 (sl) 2017-05-31
MX2010005859A (es) 2010-06-11
DK2220242T3 (en) 2017-03-27
MX344106B (es) 2016-12-05
HRP20170395T1 (hr) 2017-05-05
US20160051603A1 (en) 2016-02-25
PT2220242T (pt) 2017-04-03
CN101883857A (zh) 2010-11-10
ES2621165T3 (es) 2017-07-03
KR20100109914A (ko) 2010-10-11
HUE031636T2 (en) 2017-07-28
JP5740157B2 (ja) 2015-06-24
MX389295B (es) 2025-03-20
US20140044680A1 (en) 2014-02-13
SG10201603993TA (en) 2016-07-28
CA2706257C (en) 2017-06-06
US20100254947A1 (en) 2010-10-07
KR101662571B1 (ko) 2016-10-05
KR20150109495A (ko) 2015-10-01
JP2011504750A (ja) 2011-02-17
AU2014277699A1 (en) 2015-01-22
EP2220242A2 (en) 2010-08-25
LT2220242T (lt) 2017-04-10
KR101761683B1 (ko) 2017-07-26
JP2015107117A (ja) 2015-06-11

Similar Documents

Publication Publication Date Title
BRPI0822651A2 (pt) Subfamília b de adenovírus sadv-28, -27, 29, -32, -33 e -35 de símio e seus usos
BRPI0819774A2 (pt) Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
NL1033527A1 (nl) Röntgen-CT-apparatuur.
BRPI0915299A2 (pt) poliamida, composição compreendendo tal poliamida e utilização das mesmas
BRPI0913447A2 (pt) composição de éster, e, composição para cuidado pessoal.
BRPI0913424A2 (pt) composições agrícolas de baixa taxa de uso e métodos para o uso
BRPI0815452A2 (pt) "equipamento para gastropexia"
BRPI0923725A2 (pt) "compostos absorventes de uv trifuncionais e uso dos mesmos".
EP2366785A4 (en) OLIGONUCLEOTIDE DERIVATIVES, MARKING AGENTS AND THE MARKETING AGENT
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI0815564A2 (pt) Anticorpos que inibem a dimerização de c-met e usos dos mesmos.
BRPI0822121A2 (pt) Composição para cuidado oral, e uso da mesma
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
BRPI0818906A2 (pt) Formulação sólida de liberação rápida, preparação e uso da mesma
BRPI0922597A2 (pt) "ftalazinona e análogos relacionados como moduladores de sirtuína".
NI201000211A (es) Dronedarona para la prevención de la fibrilación auricular permanente.
IT1397595B1 (it) Sostanze coloranti e loro utilizzazione in composizioni, in particolare in composizioni cosmetiche.
BRPI0920953A2 (pt) dispositivo de manutenção, e uso do mesmo.
BRPI0813922A2 (pt) composições de inibição de influenza e métodos.
BRPI0820200A2 (pt) Composições de emulsão e composição de emulsão agroquímica
BRPI0815768A2 (pt) Uso de absorventes de uv, e, composição cosmética.
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0810265A2 (pt) "vagão ferroviáriio do tipo plataforma".
BRPI0916943A2 (pt) composição lubrificante, e, uso da mesma
BRPI0814293A2 (pt) Composição resistente ao calor, alimentação animal e uso da composição.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]